Tracer library / [177Lu]Lu-EB-PSMA-617
[177Lu]Lu-EB-PSMA-617
Also written as [Lu-177]Lu-EB-PSMA-617; Lu-177-EB-PSMA-617
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 0
What it is
- Compound class
- PSMA-targeting urea-based small molecule with Evans blue (albumin-binding) moiety, DOTA-chelated Lu-177 radioligand
- Target / mechanism
- PSMA (prostate-specific membrane antigen) PMID 35984529
- Clinical application
- PSMA-targeted radioligand therapy for PSMA-expressing adenoid cystic carcinoma PMID 35984529
- Theranostic pair
- —
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma.2022 · EJNMMI Res · Clinical study
Need this precursor?We can point you to suppliers for [177Lu]Lu-EB-PSMA-617, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 35984529: 'This pilot study was designed to evaluate the diagnostic value of 68 Ga-PSMA-617 and 18F-FDG PET/CT in adenoid cystic carcinoma (ACC) and to assess the safety and therapeutic response to PSMA radioligand therapy (RLT) in ACC patients.'. | Stage 30 (2026-09-18): Stage was 'pilot study'; normalised to 'Clinical research', original wording kept here.